Clal Finance: Teva's results disappointing - Globes - Israel Business Arena

Teva's first quarter financial are disappointing, mainly because of weak Copaxone sales and a challenging business environment in Europe, says Clal Finance analyst Jonathan Kreizman. The generic drugs giant published its first quarter results today.

TEVA's Q1 Effect on Specialty Pharma - Forbes

Teva Pharmaceuticals (TEVA), BUY – $52 target: We still see a Copaxone win as the key driver and like the risk/reward. A Copaxone win is needed and while the magnitude of upside on a win could be trimmed if EU headwinds persist (which we have ...

Can Teva Win With The Big Pharma Playbook? - Seekingalpha.com

Branded sales were up 54% as reported, with 8% growth in Copaxone. Where Teva shined was in an area that I do not believe most investors are accustomed to looking for exceptional out-performance - expense items. Gross margin improved more than a point ...

Momenta Pharmaceuticals' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - Seekingalpha.com

We have an ANDA under review for a generic Copaxone and we also have initiated a proof of concept clinical study for a novel product M402 a novel oncology product, which we are initiating a trial for in pancreatic cancer. We use intellectual property to ...

FDA Warns Of Potential Dangers Of Controversial Multiple Sclerosis Treatment - RTT News

Injectables like Teva's Copaxone, Biogen Idec's Avonex and Tysabri, and Merck Serono's Rebif and oral drug Gilenya, developed by Novartis AG, are some of the approved treatments for multiple sclerosis.

Momenta: The perfect Massachusetts success story - Boston Globe

Now Momenta is awaiting approval to sell a second generic: a version of the multiple sclerosis treatment Copaxone, made by Israel’s Teva Pharmaceutical Industries Ltd. Like generic Lovenox, the MS drug promises to reduce costs for patients and ...

Teva CFO: The new CEO will bring changes - comcast.net

Investors will soon get an answer to one of the most burning current issues at Teva: a US federal court will rule whether the company's patents for Copaxone remain valid until 2014-15, as it contends. "We're waiting for the judge's decision," said Desheh.

Prolor May Seek Partner to Market Growth Hormone Product - Bloomberg

Teva, which paid $6.5 billion to acquire U.S. biotechnology company Cephalon Inc. last year, needs new sources of revenue as its top-selling treatment, a branded multiple-sclerosis medicine called Copaxone, faces increased competition.

FDA Warns MS Patients Against Unproven Stent Procedure - Bloomberg

The condition is currently treated with medications, including Biogen Idec Inc. (BIIB)’s Avonex and Tysabri and Teva Pharmaceutical Industries Ltd. (TEVA)’s Copaxone. To contact the reporter on this story: Michelle Fay Cortez in Minneapolis ...

Canaccord Genuity on Specialty Pharma: TEVA's Q1 Effect on Specialty Pharma (TEVA, WPI, PRGO & MYL) - StreetInsider.com

TEVA (Nasdaq: TEVA) (BUY - $52 target): We still see a Copaxone win as the key driver and like the risk/reward. A Copaxone win is needed and while the magnitude of upside on a win could be trimmed if EU headwinds persist (which we have to assume), we still ...